Sernova Corp. Selected for the TSX Venture Stock Exchange’s 2021 Venture 50 List of Top Performing Listed Companies

NewsBy TechAllianceFebruary 25, 2021

Sernova Corp., a clinical-stage company and leader in regenerative medicine therapeutics is pleased to announce that the TSX Venture Stock Exchange (TSX Venture) has recognized Sernova as a 2021 Venture 50 company, showcasing the top 50 performing listed companies. “We are honoured to be chosen for the 2021 Venture 50 list and to be included…

Sernova Obtains Final Prospectus Receipt for $20 Million Bought Deal

NewsBy TechAllianceFebruary 25, 2021

Sernova Corp., a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce it has received a receipt for its final short form prospectus dated February 24, 2021 (the “Final Prospectus”) in connection with its previously announced bought deal offering of 16,700,000 units of the Company (the “Units”) at a price of C$1.20 per Unit…